What is Biogen?
Biotechnology and neuroscience company with $9.9B 2025 revenue scale and public-market buying capacity.
- Category
- Biotechnology and neuroscience
- Headquarters
- Cambridge, MA
- Founded
- 1978
- Employees
- 7,500+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: BIIB; Public company
What is Biogen?
Biogen is a public biotechnology and neuroscience company headquartered in Cambridge, MA. Biogen reported 2025 revenue of about $9.9 billion, with growth products helping offset legacy multiple-sclerosis pressure.
Biogen operates in biotechnology and neuroscience with a portfolio that includes Leqembi collaboration, Spinraza, Skyclarys, Qalsody. Biogen reported 2025 revenue of about $9.9 billion, with growth products helping offset legacy multiple-sclerosis pressure. The company employs about 7,500+ and trades as Nasdaq: BIIB, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Biogen through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Biogen is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Biogen offer?
Biogen offers products and services across Leqembi collaboration, Spinraza, Skyclarys, Qalsody and related healthcare workflows.
- Leqembi collaboration· Alzheimer's disease
- Spinraza· Rare disease
- Skyclarys· Rare disease
- Qalsody· ALS
- Multiple sclerosis portfolio· Neuroscience
- Zurzuvae collaboration· Neuropsychiatry
How does Biogen make money?
Biogen earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Biogen earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $9.9B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Biogen improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Biogen?
Biogen is led by Christopher Viehbacher, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Christopher ViehbacherPresident and Chief Executive OfficerCEO since 2022Leads Biogen's portfolio reset in neuroscience, rare disease, and immunology.
- Robin KramerChief Financial OfficerCFO in 2026Oversees financial planning and capital allocation.
- Priya SinghalHead of DevelopmentSenior R&D leaderGuides clinical development and medical priorities.
- Jane GroganHead of ResearchResearch leaderLeads discovery and translational research.
How do you contact Biogen's leadership?
Biogen publishes official Biogen investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Biogen investor-relations contact route; personal executive email format not verified- Christopher ViehbacherPresident and Chief Executive Officerofficial Biogen investor-relations contact route
Sources:Biogen contactBiogen leadership
How much funding has Biogen raised?
Biogen is a mature public company, not a venture-backed startup. It trades as Nasdaq: BIIB and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Biogen's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: BIIB, $9.9B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Biogen has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Biogen get here?
Biogen grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1978Biogen foundedA group of scientists forms Biogen in Geneva.
- 1983IPOBiogen becomes a public biotechnology company.
- 1996Avonex approvedBiogen becomes a leader in multiple sclerosis.
- 2022Christopher Viehbacher becomes CEOBiogen begins a strategic reset.
- 2025$9.9B revenueBiogen reports about $9.9 billion of 2025 revenue.
- 2026Apellis acquisition announcedBiogen agrees to acquire Apellis for approximately $5.6 billion.
Who are Biogen's competitors?
Biogen competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- RocheCompetes in neuroscience, multiple sclerosis, and Alzheimer's-related care.
- EisaiCollaborates and competes in Alzheimer's and neuroscience commercialization.
- NovartisCompetes in neuroscience, immunology, and specialty medicines.
- SanofiCompetes in immunology, rare disease, and specialty-biopharma markets.
- AmgenCompetes in biologics, neuroscience-adjacent assets, and payer access.
- Bristol Myers SquibbCompetes in immunology, neuroscience, and specialty-biopharma budgets.
Biogen — frequently asked questions
